肝外胆管癌放疗的研究进展

摘要/Abstract

摘要：

肝外胆管癌是一种较为罕见的消化系统恶性肿瘤,其复发率高,预后差。随着现代医学和放疗技术的发展,放疗联合手术、化疗、胆道支架等在可切除及不可切除的肝外胆管癌治疗过程中占据越来越重要的地位。目前已有大量研究显示外照射放疗、近距离腔内放疗、立体定向放疗等多种放疗技术具有良好的安全性和疗效,但其临床应用仍存在争议。

关键词:胆管肿瘤,放射疗法,治疗结果

Abstract:

Extrahepatic cholangiocarcinoma is a rare, aggressive malignancy of the digestive system with high recurrence rate and poor prognosis. With the development of modern medicine and radiotherapy technology, combined with surgery, chemotherapy, and biliary stent,etc., radiotherapy plays a more and more important role in the treatment of resectable and unresectable patients. At present, a large number of studies have shown that external beam radiotherapy, intraluminal brachytherapy, stereotactic body radiation therapy and other kinds of radiotherapy techniques have good safety and efficacy, but its clinical application is still controversial.

Key words:Bile duct neoplasms,Radiotherapy,Treatment outcome

周蔚文, 孙晓南. 肝外胆管癌放疗的研究进展[J]. 国际肿瘤学杂志, 2020, 47(7): 431-435.

Zhou Weiwen, Sun Xiaonan. Research progress of radiotherapy in extrahepatic cholangiocarcinoma[J]. Journal of International Oncology, 2020, 47(7): 431-435.

参考文献38

[1]	Valle JW, Borbath I, Khan SA, et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2016,27(suppl 5):v28-v37. DOI: 10.1093/annonc/mdw324. doi:10.1093/annonc/mdw324pmid:27664259
[2]	Gkika E, Hallauer L, Kirste S, et al. Stereotactic body radiotherapy (SBRT) for locally advanced intrahepatic and extrahepatic cholangiocarcinoma[J]. BMC Cancer, 2017,17:781. DOI: 10.1186/s12885-017-3788-1. doi:10.1186/s12885-017-3788-1pmid:29162055
[3]	Bridgewater JA, Goodman KA, Kalyan A, et al. Biliary tract cancer: epidemiology, radiotherapy, and molecular profiling[J]. Am Soc Clin Oncol Educ Book, 2016,35:e194-e203. DOI: 10.1200/EDBK_160831. doi:10.1200/EDBK_160831pmid:27249723
[4]	Sallinen V, Sirén J, Mäkisalo H, et al. Differences in prognostic factors and recurrence patterns after curative-intent resection of perihilar and distal cholangiocarcinomas[J]. Scand J Surg, 2019: 1457496919832150. DOI: 10.1177/1457496919832150.
[5]	Ghiassi-Nejad Z, Tarchi P, Moshier E, et al. Prognostic factors and patterns of locoregional failure after surgical resection in patients with cholangiocarcinoma without adjuvant radiation therapy: optimal field design for adjuvant radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2017,99(4):805-811. DOI: 10.1016/j.ijrobp.2017.06.2467. doi:10.1016/j.ijrobp.2017.06.2467pmid:29063849
[6]	National Comprehensive Cancer Network. NCCN Clinical Practice Guideline in Oncology: Hepatobiliary Cancers (Verion 4.2019)[EB/OL]. [ 2019- 12- 20]. http://www.nccn.org.
[7]	Wellner UF, Shen Y, Keck T, et al. The survival outcome and prognostic factors for distal cholangiocarcinoma following surgical resection: a meta-analysis for the 5-year survival[J]. Surg Today, 2017,47(3):271-279. DOI: 10.1007/s00595-016-1362-0. doi:10.1007/s00595-016-1362-0pmid:27236779
[8]	Kim BH, Kim K, Chie EK, et al. Long-term outcome of distal cholangiocarcinoma after pancreaticoduodenectomy followed by adjuvant chemoradiotherapy: a 15-year experience in a single institution[J]. Cancer Res Treat, 2017,49(2):473-483. DOI: 10.4143/crt.2016.166. doi:10.4143/crt.2016.166pmid:27554480
[9]	Ecker BL, Vining CC, Roses RE, et al. Identification of patients for adjuvant therapy after resection of carcinoma of the extrahepatic bile ducts: a propensity score-matched analysis[J]. Ann Surg Oncol, 2017,24(13):3926-3933. DOI: 10.1245/s10434-017-6095-9. pmid:28952140
[10]	Hester C, Nassour I, Adams-Huet B, et al. Improved survival in surgically resected distal cholangiocarcinoma treated with adjuvant therapy: a propensity score matched analysis[J]. J Gastrointest Surg, 2018,22(12):2080-2087. DOI: 10.1007/s11605-018-3875-x. doi:10.1007/s11605-018-3875-xpmid:30030718
[11]	Dover LL, Oster RA, Mcdonald AM, et al. Impact of adjuvant chemoradiation on survival in patients with resectable cholangio-carcinoma[J]. HPB (Oxford), 2016,18(10):843-850. DOI: 10.1016/j.hpb.2016.07.008. doi:10.1016/j.hpb.2016.07.008
[12]	Kim YS, Hwang IG, Park SE, et al. Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma[J]. Cancer Chemother Pharmacol, 2016,77(5):979-985. DOI: 10.1007/s00280-016-3014-x. pmid:27017615
[13]	Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: a phase Ⅱ intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma[J]. J Clin Oncol, 2015,33(24):2617-2622. DOI: 10.1200/JCO.2014.60.2219. doi:10.1200/JCO.2014.60.2219pmid:25964250
[14]	Petrova E, Rückert F, Zach S, et al. Survival outcome and prognostic factors after pancreatoduodenectomy for distal bile duct carcinoma: a retrospective multicenter study[J]. Langenbecks Arch Surg, 2017,402(5):831-840. DOI: 10.1007/s00423-017-1590-9. doi:10.1007/s00423-017-1590-9pmid:28612115
[15]	Jung JH, Lee HJ, Lee HS, et al. Benefit of neoadjuvant concurrent chemoradiotherapy for locally advanced perihilar cholangiocarcinoma[J]. World J Gastroenterol, 2017,23(18):3301-3308. DOI: 10.3748/wjg.v23.i18.3301. doi:10.3748/wjg.v23.i18.3301pmid:28566890
[16]	Sumiyoshi T, Shima Y, Okabayashi T, et al. Chemoradiotherapy for initially unresectable locally advanced cholangiocarcinoma[J]. World J Surg, 2018,42(9):2910-2918. DOI: 10.1007/s00268-018-4558-1. pmid:29511872
[17]	Zamora-Valdes D, Heimbach JK. Liver transplant for cholangiocarcinoma[J]. Gastroenterol Clin North Am, 2018,47(2):267-280. DOI: 10.1016/j.gtc.2018.01.002. doi:10.1016/j.gtc.2018.01.002pmid:29735023
[18]	Frosio F, Mocchegiani F, Conte G, et al. Neoadjuvant therapy in the treatment of hilar cholangiocarcinoma: review of the literature[J]. World J Gastrointest Surg, 2019,11(6):279-286. DOI: 10.4240/wjgs.v11.i6.279. doi:10.4240/wjgs.v11.i6.279pmid:31367275
[19]	Croome KP, Rosen CB, Heimbach JK, et al. Is liver transplantation appropriate for patients with potentially resectable de novo hilar cholangiocarcinoma?[J]. J Am Coll Surg, 2015,221(1):130-139. DOI: 10.1016/j.jamcollsurg.2015.01.064. doi:10.1016/j.jamcollsurg.2015.01.064pmid:25872685
[20]	Ethun CG, Lopez-Aguiar AG, Anderson DJ, et al. Transplantation versus resection for hilar cholangiocarcinoma: an argument for shifting treatment paradigms for resectable disease[J]. Ann Surg, 2018,267(5):797-805. DOI: 10.1097/SLA.0000000000002574. doi:10.1097/SLA.0000000000002574pmid:29064885
[21]	Moris D, Kostakis ID, Machairas N, et al. Comparison between liver transplantation and resection for hilar cholangiocarcinoma: a systematic review and meta-analysis[J]. PLoS One, 2019,14(7):e0220527. DOI: 10.1371/journal.pone.0220527. doi:10.1371/journal.pone.0220527pmid:31365594
[22]	Mantel HT, Westerkamp AC, Adam R, et al. Strict selection alone of patients undergoing liver transplantation for hilar cholangio-carcinoma is associated with improved survival[J]. PLoS One, 2016,11(6):e0156127. DOI: 10.1371/journal.pone.0156127. doi:10.1371/journal.pone.0156127pmid:27276221
[23]	Assistance Publique. Liver resection versus radio-chemotherapy-transplantation for hilar cholangiocarcinoma (TRANSPHIL)[EB/OL]. [2020-1-20]. https://clinicaltrials.gov/ct2/show/study/NCT02232932.
[24]	Bolm L, Kaesmann L, Bartscht T, et al. Outcomes after radio(chemo)therapy for non-metastatic bile duct cancer[J]. In Vivo, 2017,31(1):117-120. DOI: 10.21873/invivo.11033. pmid:28064229
[25]	Autorino R, Mattiucci GC, Ardito F, et al. Radiochemotherapy with gemcitabine in unresectable extrahepatic cholangiocarcinoma: long-term results of a phase Ⅱ study[J]. Anticancer Res, 2016,36(2):737-740. pmid:26851032
[26]	Torgeson A, Lloyd S, Boothe D, et al. Chemoradiation therapy for unresected extrahepatic cholangiocarcinoma: a propensity score-matched analysis[J]. Ann Surg Oncol, 2017,24(13):4001-4008. DOI: 10.1245/s10434-017-6131-9. doi:10.1245/s10434-017-6131-9pmid:29043526
[27]	Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study[J]. Lancet Oncol, 2019,20(5):663-673. DOI: 10.1016/S1470-2045(18)30915-X. doi:10.1016/S1470-2045(18)30915-Xpmid:30922733
[28]	Tao R, Krishnan S, Bhosale PR, et al. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoper-able intrahepatic cholangiocarcinoma: a retrospective dose response analysis[J]. J Clin Oncol, 2016,34(3):219-226. DOI: 10.1200/JCO.2015.61.3778. doi:10.1200/JCO.2015.61.3778pmid:26503201
[29]	Skowronek J, Zwierzchowski G. Brachytherapy in the treatment of bile duct cancer—a tough challenge[J]. J Contemp Brachytherapy, 2017,9(2):187-195. DOI: 10.5114/jcb.2017.66893. pmid:28533809
[30]	Tan Y, Zhu JY, Qiu BA, et al. Percutaneous biliary stenting combined with radiotherapy as a treatment for unresectable hilar cholangiocarcinoma[J]. Oncol Lett, 2015,10(4):2537-2542. DOI: 10.3892/ol.2015.3589. doi:10.3892/ol.2015.3589pmid:26622885
[31]	Xu X, Li J, Wu J, et al. A systematic review and meta-analysis of intraluminal brachytherapy versus stent alone in the treatment of malignant obstructive jaundice[J]. Cardiovasc Intervent Radiol, 2018,41(2):206-217. DOI: 10.1007/s00270-017-1827-6. doi:10.1007/s00270-017-1827-6pmid:29075881
[32]	Nguyen NA, Timotin E, Hunter R, et al. High-dose rate intraluminal brachytherapy: an effective palliation for cholangiocarcinoma causing bile duct obstruction[J]. Surg Oncol, 2018,27(4):625-629. DOI: 10.1016/j.suronc.2018.07.004. doi:10.1016/j.suronc.2018.07.004pmid:30449482
[33]	Feng M, Suresh K, Schipper MJ, et al. Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage: a phase 2 clinical trial[J]. JAMA Oncol, 2018,4(1):40-47. DOI: 10.1001/jamaoncol.2017.2303. doi:10.1001/jamaoncol.2017.2303pmid:28796864
[34]	Venkat PS, Hoffe SE, Frakes JM. Stereotactic body radiation therapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J]. Cancer Control, 2017,24(3):1073274817729259. DOI: 10.1177/1073274817729259. doi:10.1177/1073274817729259pmid:28975831
[35]	Mahadevan A, Dagoglu N, Mancias J, et al. Stereotactic body radiotherapy (SBRT) for intrahepatic and hilar cholangiocarcinoma[J]. J Cancer, 2015,6(11):1099-1104. DOI: 10.7150/jca.13032. pmid:26516357
[36]	Sandler KA, Veruttipong D, Agopian VG, et al. Stereotactic body radiotherapy (SBRT) for locally advanced extrahepatic and intra-hepatic cholangiocarcinoma[J]. Adv Radiat Oncol, 2016,1(4):237-243. DOI: 10.1016/j.adro.2016.10.008. pmid:28740893
[37]	Frakulli R, Buwenge M, Macchia G, et al. Stereotactic body radiation therapy in cholangiocarcinoma: a systematic review[J], 2019,92(1097):20180688. DOI: 10.1259/bjr.20180688.
[38]	Brunner TB, Blanck O, Lewitzki V, et al. Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma[J]. Radiother Oncol, 2019,132:42-47. DOI: 10.1016/j.radonc.2018.11.015. doi:10.1016/j.radonc.2018.11.015pmid:30825968

Research progress of radiotherapy in extrahepatic cholangiocarcinoma

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献38

相关文章15

编辑推荐

Metrics

本文评价

[1]	钱晓涛, 石子宜, 胡格, 吴晓维.Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[3]	王昆, 周中新, 臧其威.血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[4]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛.索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[5]	严爱婷, 王翠竹, 刘春桂, 鲁小敏.卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[6]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵.寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[7]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安.新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[8]	姜溪, 武永存, 梁艳, 楚丽, 段颖欣, 王力军, 霍俊杰.派安普利单抗联合化疗对晚期非小细胞肺癌患者血管生成及循环内皮细胞的影响[J]. 国际肿瘤学杂志, 2024, 51(2): 89-94.
[9]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会.中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[10]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟.基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[11]	崔腾璐, 吕璐, 孙鹏飞.放疗联合免疫治疗在头颈部鳞状细胞癌治疗中的应用[J]. 国际肿瘤学杂志, 2023, 50(9): 548-552.
[12]	黄辉, 丁江华.靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573.
[13]	李青珊, 谢鑫, 张楠, 刘帅.放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[14]	许萌, 姜伟, 朱海涛, 曹雄锋.癌相关成纤维细胞在肿瘤放疗抵抗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 227-230.
[15]	石小琪, 汪红艳.肠道菌群与放射性肠炎的相互作用及研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 244-247.